PE endothelium - Medicine bibliographies - in Harvard style

In-text: (Ahmad and Ahmed, 2005)

Your Bibliography: Ahmad, S. and Ahmed, A., 2005. Antiangiogenic Effect of Soluble Vascular Endothelial Growth Factor Receptor-1 in Placental Angiogenesis. Endothelium, 12(1-2), pp.89-95.

In-text: (Bellamy, Casas, Hingorani and Williams, 2008)

Your Bibliography: Bellamy, L., Casas, J., Hingorani, A. and Williams, D., 2008. Preeclampsia and Risk of Cardiovascular Disease and Cancer in Later Life: Systematic Review and Meta-analysis. Obstetric Anesthesia Digest, 28(2), p.80.

In-text: (Chaiworapongsa et al., 2004)

Your Bibliography: Chaiworapongsa, T., Romero, R., Espinoza, J., Bujold, E., Mee Kim, Y., Gonçalves, L., Gomez, R. and Edwin, S., 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. American Journal of Obstetrics and Gynecology, 190(6), pp.1541-1547.

In-text: (Ferrara, 2009)

Your Bibliography: Ferrara, N., 2009. Vascular Endothelial Growth Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), pp.789-791.

In-text: (Koga et al., 2003)

Your Bibliography: Koga, K., Osuga, Y., Yoshino, O., Hirota, Y., Ruimeng, X., Hirata, T., Takeda, S., Yano, T., Tsutsumi, O. and Taketani, Y., 2003. Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia. The Journal of Clinical Endocrinology & Metabolism, 88(5), pp.2348-2351.

In-text: (Levine et al., 2004)

Your Bibliography: Levine, R., Qian, C., Maynard, S., Yu, K., Epstein, F., Karumanchi, S., Lim, K., Schisterman, E., Thadhani, R., Sachs, B., Sibai, B. and Sukhatme, V., 2004. Circulating angiogenic factors and the risk of preeclampsia*. Obstetrics & Gynecology, 103(5, Part 1), p.993.

In-text: (Maynard et al., 2003)

Your Bibliography: Maynard, S., Min, J., Merchan, J., Lim, K., Li, J., Mondal, S., Libermann, T., Morgan, J., Sellke, F., Stillman, I., Epstein, F., Sukhatme, V. and Karumanchi, S., 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 111(5), pp.649-658.

In-text: (McKeeman et al., 2004)

Your Bibliography: McKeeman, G., Ardill, J., Caldwell, C., Hunter, A. and McClure, N., 2004. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. American Journal of Obstetrics and Gynecology, 191(4), pp.1240-1246.

In-text: (Tsatsaris et al., 2003)

Your Bibliography: Tsatsaris, V., Goffin, F., Munaut, C., Brichant, J., Pignon, M., Noel, A., Schaaps, J., Cabrol, D., Frankenne, F. and Foidart, J., 2003. Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological Consequences. The Journal of Clinical Endocrinology & Metabolism, 88(11), pp.5555-5563.

In-text: (VUORELA et al., 2000)

Your Bibliography: VUORELA, P., HELSKE, S., HORNIG, C., ALITALO, K., WEICH, H. and HALMESMÄKI, E., 2000. Amniotic Fluid–Soluble Vascular Endothelial Growth Factor Receptor-1 in Preeclampsia. Obstetrics & Gynecology, 95(3), pp.353-357.

In-text: (Zhou et al., 2002)

Your Bibliography: Zhou, Y., McMaster, M., Woo, K., Janatpour, M., Perry, J., Karpanen, T., Alitalo, K., Damsky, C. and Fisher, S., 2002. Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome. The American Journal of Pathology, 160(4), pp.1405-1423.